Long term RZB provides durable efficacy response in PsA through 100 weeks. No new safety signals. Abs 2145 #ACR22 @RheumNow https://t.co/HfJvS1HzDW https://t.co/T67lDnxeLy
Links:
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Re…
http://ow.ly/wvfu50LAllK
14-11-2022